China, Aug. 11 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Study on the Role of Omalizumab in Children with Severe Allergic Reactions'. The following are the other relevant details related to the trial:
Registration Number: ChiCTR2600129505
Registration Time: 2026/08/05
Type: Observational study
Primary Sponsor: The First Affiliated Hospital of Xi'an Jiaotong University
To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=327686
Published by HT Digital Content Services with permission from Health Daily Digest....